Trillium Therapeutics Company Profile (NASDAQ:TRIL)

About Trillium Therapeutics (NASDAQ:TRIL)

Trillium Therapeutics logo

Industry, Sector and Symbol: Capitalization:
  • Market Cap: $39.23 million
  • Outstanding Shares: 7,845,000
Average Prices:
  • 50 Day Moving Avg: $6.04
  • 200 Day Moving Avg: $6.25
  • 52 Week Range: $4.50 - $17.70
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -1.52
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $2.44 per share
  • Price / Book: 2.05
Profitability:
  • EBIDTA: ($21,380,000.00)
  • Return on Equity: -57.62%
  • Return on Assets: -30.72%
Debt:
  • Debt-to-Equity Ratio: 0.01%
  • Current Ratio: 11.72%
  • Quick Ratio: 11.72%
Misc:
  • Average Volume: 50,287 shs.
  • Beta: 1
  • Short Ratio: 4.82
 

Frequently Asked Questions for Trillium Therapeutics (NASDAQ:TRIL)

What is Trillium Therapeutics' stock symbol?

Trillium Therapeutics trades on the NASDAQ under the ticker symbol "TRIL."

Where is Trillium Therapeutics' stock going? Where will Trillium Therapeutics' stock price be in 2017?

6 analysts have issued 1 year target prices for Trillium Therapeutics' stock. Their forecasts range from $18.00 to $38.00. On average, they expect Trillium Therapeutics' share price to reach $24.25 in the next year. View Analyst Ratings for Trillium Therapeutics.

What are analysts saying about Trillium Therapeutics stock?

Here are some recent quotes from research analysts about Trillium Therapeutics stock:

  • 1. According to Zacks Investment Research, "Trillium Therapeutics Inc. is a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer. The company's lead program, SIRPaFc (TTI-621), is a fusion protein that consists of the CD47-binding domain of human SIRPa linked to the Fc region of a human immunoglobulin (IgG1). It is designed to act as a soluble decoy receptor, preventing CD47 from delivering its inhibitory (do not eat) signal. Neutralization of the inhibitory CD47 signal enables the activation of macrophage anti-tumor effects by pro-phagocytic (eat) signals. A Phase 1 clinical trial (NCT02663518) evaluating SIRPaFc is ongoing. Trillium also has a proprietary medicinal chemistry platform, using unique fluorine chemistry, which permits the creation of new chemical entities from validated drugs and drug candidates with improved pharmacological properties. " (4/6/2017)
  • 2. Cowen and Company analysts commented, "The key investor concern coming into ASH was safety of the 0.2mg/kg/week dose of." (12/5/2016)
  • 3. Ladenburg Thalmann Financial Services analysts commented, "an attractive investment opportunity in the immuno-oncology space with substantial upside potential and multiple downside protection."Further, the target price of $18 represents a potential upside of 95 percent over Tuesday's close of $9.21.Toronto-based Trillium is an immuno-oncology-focused company developing innovative therapies for cancer. Its lead program, TTI-621, is a antibody-like fusion protein targeting CD47, the blockade of which is shown to have improved anti-tumor phagocytosis and innate immunity. "We expect TTI-621 to likely show better safety, higher potency and/or more favorable PK profile than the other lead competitors, and have best-in-class potential," analyst Wangzhi Li said.Related Link: Biogen, Ionis Reveal Nusinersen Meets Primary Endpoint At Interim Analysis Of Final Stage ENDEAR TrialLi noted that the current market values Trillium at about $45 million–$95 million, exclusive of its current cash (about $45 million). In fact, the analyst said the upfront payments alone were over $200 million for the co-development/promotion partnership rights to a number of similar immune-oncology programs at preclinical or Phase 1 stage.Li sees escalation in partnership interest with Trillium if TTI-621 shows positive results in Phase 1 study.The analyst noted that there is multiple downside protection to the stock in the form of sufficient cash balance, CD200 mAb platform, fluorine-based medicinal chemistry platform and a pipeline of small molecules directed at immuno-oncology targets."Our modeling indicates the downside valuation of TRIL is protected at over $50 million, or over $4.70 per diluted share, even in the potential scenario of writing off the TT1-621 program," (8/3/2016)

Are investors shorting Trillium Therapeutics?

Trillium Therapeutics saw a increase in short interest in the month of April. As of April 28th, there was short interest totalling 309,462 shares, an increase of 1.1% from the April 13th total of 306,145 shares. Based on an average trading volume of 31,254 shares, the short-interest ratio is currently 9.9 days.

Who are some of Trillium Therapeutics' key competitors?

Who owns Trillium Therapeutics stock?

Trillium Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Janus Capital Management LLC (6.93%), Candriam Luxembourg S.C.A. (1.40%), Victory Capital Management Inc. (0.99%), Creative Planning (0.33%) and Wells Fargo & Company MN (0.23%). View Institutional Ownership Trends for Trillium Therapeutics.

Who sold Trillium Therapeutics stock? Who is selling Trillium Therapeutics stock?

Trillium Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Janus Capital Management LLC. View Insider Buying and Selling for Trillium Therapeutics.

Who bought Trillium Therapeutics stock? Who is buying Trillium Therapeutics stock?

Trillium Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including Victory Capital Management Inc. and Wells Fargo & Company MN. View Insider Buying and Selling for Trillium Therapeutics.

How do I buy Trillium Therapeutics stock?

Shares of Trillium Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Trillium Therapeutics stock cost?

One share of Trillium Therapeutics stock can currently be purchased for approximately $5.00.

Analyst Ratings

Consensus Ratings for Trillium Therapeutics (NASDAQ:TRIL) (?)
Ratings Breakdown: 6 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $24.25 (385.00% upside)

Analysts' Ratings History for Trillium Therapeutics (NASDAQ:TRIL)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
12/5/2016Cowen and CompanyReiterated RatingBuyN/AView Rating Details
11/4/2016Bloom BurtonReiterated RatingBuyN/AView Rating Details
11/3/2016Leerink SwannReiterated RatingOutperform$20.00N/AView Rating Details
10/6/2016BTIG ResearchInitiated CoverageBuy$21.00N/AView Rating Details
8/3/2016Ladenburg Thalmann Financial ServicesInitiated CoverageBuy$18.00N/AView Rating Details
6/6/2016Oppenheimer Holdings Inc.Reiterated RatingBuy$38.00N/AView Rating Details
(Data available from 5/27/2015 forward)

Earnings

Earnings History for Trillium Therapeutics (NASDAQ:TRIL)
No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for Trillium Therapeutics (NASDAQ:TRIL)
2017 EPS Consensus Estimate: ($2.98)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.80)($0.80)($0.80)
Q2 20171($0.83)($0.83)($0.83)
Q3 20171($0.83)($0.83)($0.83)
Q4 20171($0.52)($0.52)($0.52)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Trillium Therapeutics (NASDAQ:TRIL)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Trillium Therapeutics (NASDAQ:TRIL)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for Trillium Therapeutics (NASDAQ:TRIL)
Latest Headlines for Trillium Therapeutics (NASDAQ:TRIL)
Source:
DateHeadline
americanbankingnews.com logoTrillium Therapeutics Inc. (TRIL) Short Interest Up 1.1% in April
www.americanbankingnews.com - May 17 at 8:56 PM
finance.yahoo.com logoTrillium Reports First Quarter 2017 Financial and Operating Results
finance.yahoo.com - May 13 at 2:09 AM
americanbankingnews.com logoTrillium Therapeutics Inc. (TRIL) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - May 12 at 7:58 AM
americanbankingnews.com logoZacks: Analysts Anticipate Trillium Therapeutics Inc. (TRIL) to Announce -$1.04 EPS
www.americanbankingnews.com - May 4 at 1:07 AM
americanbankingnews.com logoTrillium Therapeutics (TRIL) Earning Somewhat Positive Press Coverage, Study Finds
www.americanbankingnews.com - May 2 at 5:44 PM
americanbankingnews.com logo Brokerages Expect Trillium Therapeutics Inc. (TRIL) to Post -$1.04 Earnings Per Share
www.americanbankingnews.com - April 28 at 9:10 AM
americanbankingnews.com logoTrillium Therapeutics (TRIL) Earning Somewhat Critical Media Coverage, Report Finds
www.americanbankingnews.com - April 27 at 1:06 PM
americanbankingnews.com logoTrillium Therapeutics (TRIL) Receives Daily News Sentiment Score of 0.57
www.americanbankingnews.com - April 22 at 7:47 AM
americanbankingnews.com logoTrillium Therapeutics (TRIL) Earning Somewhat Favorable Press Coverage, Analysis Finds
www.americanbankingnews.com - April 18 at 2:40 PM
americanbankingnews.com logoTrillium Therapeutics Inc. (TRIL) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - April 17 at 9:02 AM
americanbankingnews.com logoTrillium Therapeutics (TRIL) Receiving Positive Press Coverage, Analysis Finds
www.americanbankingnews.com - April 14 at 4:53 PM
americanbankingnews.com logoLeerink Swann Comments on Trillium Therapeutics Inc.'s Q1 2017 Earnings (TRIL)
www.americanbankingnews.com - April 12 at 8:18 AM
americanbankingnews.com logoZacks: Analysts Anticipate Trillium Therapeutics Inc. (TRIL) to Post -$1.28 Earnings Per Share
www.americanbankingnews.com - April 7 at 5:56 PM
americanbankingnews.com logoTrillium Therapeutics Inc. (TRIL) Raised to Hold at Zacks Investment Research
www.americanbankingnews.com - April 6 at 1:55 PM
reuters.com logoBRIEF-Trillium Therapeutics presents TTI-621 preclinical data at AACR annual meeting
www.reuters.com - April 4 at 1:11 AM
streetinsider.com logoTrillium Therapeutics (TRIL) Highlights TTI-621 Preclinical Data at ... - StreetInsider.com
www.streetinsider.com - April 3 at 8:09 PM
finance.yahoo.com logoTrillium Therapeutics to Present at Investor and Scientific Conferences in April
finance.yahoo.com - March 29 at 7:41 AM
americanbankingnews.com logoTrillium Therapeutics Inc. (TRIL) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - March 21 at 1:00 PM
finance.yahoo.com logoTRILLIUM THERAPEUTICS INC. Financials
finance.yahoo.com - March 15 at 10:26 PM
finance.yahoo.com logoTrillium Therapeutics to Present at Investor and Scientific Conferences in February
finance.yahoo.com - February 8 at 8:04 AM
streetinsider.com logoTrillium Therapeutics (TRIL) Outlines 2017 Anticipated Activities and Milestones
www.streetinsider.com - February 3 at 6:19 AM
reuters.com logoBRIEF-Trillium Therapeutics Inc intends to provide an update on ongoing TTI-621 trials
www.reuters.com - February 3 at 6:19 AM
finance.yahoo.com logoTrillium Therapeutics Outlines Anticipated Activities and Milestones for 2017
finance.yahoo.com - February 3 at 6:19 AM
finance.yahoo.com logo7:15 am Trillium Therapeutics outlines its expected 2017 activities and milestones
finance.yahoo.com - February 3 at 6:19 AM
reuters.com logoBRIEF-Trillium Therapeutics doses first patient with TTI-621 in phase 1 solid tumor trial
www.reuters.com - February 1 at 7:00 AM
streetinsider.com logoTrillium Therapeutics (TRIL) Initiates Dosing in Second Phase 1 Trial of TTI-621
www.streetinsider.com - February 1 at 7:00 AM
finance.yahoo.com logoTrillium Therapeutics Doses First Patient With TTI-621 in Phase 1 Solid Tumor Trial
finance.yahoo.com - February 1 at 7:00 AM
streetinsider.com logoTrillium Therapeutics (TRIL) Announces Presentation of Initial TTI-621 Data in AMMs
www.streetinsider.com - December 5 at 8:37 AM
us.rd.yahoo.com logo1:46 am Trillium Therapeutics presents initial data from ongoing study of TTI-621; believes data from this study provide preliminary evidence that TTI-621 monotherapy is both active and well tolerated
us.rd.yahoo.com - December 5 at 8:37 AM
finance.yahoo.com logoTrillium Presents Initial Data From Ongoing Study of …
finance.yahoo.com - December 4 at 8:30 AM
finance.yahoo.com logoTrillium Presents Initial Data From Ongoing Study of TTI-621 in Patients With Advanced Hematologic Malignancies at the American Society of Hematology Annual Meeting
finance.yahoo.com - December 3 at 7:12 PM

Social

Chart

Trillium Therapeutics (TRIL) Chart for Saturday, May, 27, 2017

This page was last updated on 5/27/2017 by MarketBeat.com Staff